Loading
Hemangeol is a liquid form of the blood-pressure drug propranolol approved to shrink infantile haemangiomas, the common benign blood-vessel tumours of babies, replacing steroids and surgery for most children who need treatment.
Propranolol oral solution (Hemangeol) was approved in the United States in 2014 for proliferating infantile haemangioma requiring systemic therapy, after a chance observation in 2008 that the beta-blocker shrank these benign vascular tumours. Infantile haemangiomas are the commonest tumours of infancy and most need no treatment, but those threatening vision, breathing or feeding, or ulcerating, respond within weeks. Propranolol has since been studied in angiosarcoma and other vascular cancers on the same rationale, without approval. Low blood sugar, slow heart rate and low blood pressure are the main risks in infants.
Blocks beta-adrenergic receptors on the endothelial cells of a proliferating haemangioma, causing vasoconstriction, lower VEGF signalling and apoptosis of the abnormal vessels. Connects to VEGF / VEGFR.
1.Propranolol (Hemangeol) slips into a pocket on VEGF / VEGFR.
| Region | Year | Indication |
|---|---|---|
| US | 2014 | Proliferating infantile haemangioma requiring systemic therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Propranolol" OR ABSTRACT:"Propranolol" OR TITLE:"Hemangeol" OR ABSTRACT:"Hemangeol" OR TITLE:"Propranolol Hydrochloride" OR ABSTRACT:"Propranolol Hydrochloride" OR TITLE:"Propranolol oral solution" OR ABSTRACT:"Propranolol oral solution") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Propranolol (Hemangeol), not a curated reading list.